Gritstone bio Announces Presentations Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 at ECCMID 2023

April 4, 2023

https://www.globenewswire.com/news-release/2023/04/04/2641270/0/en/Gritstone-bio-Announces-Presentations-Evaluating-Self-amplifying-mRNA-samRNA-Against-SARS-CoV-2-at-ECCMID-2023.html

EMERYVILLE, Calif., April 04, 2023 (GLOBE NEWSWIRE) — Gritstone bio, Inc. (Nasdaq:GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced multiple presentations at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023), taking place April 15-18, 2023 in Copenhagen, Denmark. Both presentations are from the company’s CORAL program, which is evaluating various self-amplifying mRNA (samRNA) vaccine candidates targeting Spike in addition to other viral genes of SARS-CoV-2. The program aims to serve as proof-of-concept for Gritstone’s infectious disease vaccine approach and the potential application of samRNA against infectious diseases.

Read more at globenewswire.com

Related news for (GRTS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.